Positive long-term results for Bristol-Myers Squibb's Nulojix in organ rejection
US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday presented the data at the 2012 American Transplant Congress in Boston, showing that Nulojix (belatacept), its treatment to prevent organ rejection in patients receiving kidney transplants, was found as safe and effective after four years as in a study of patients after three years.
Nulojix was approved by both US and European regulators last summer for the prevention of acute rejection in adult patients who have had a kidney transplant (The Pharma Letters June 16 and 21, 2011). The product has been forecast to achieve annual sales of $650 million by 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze